研究者
J-GLOBAL ID：201901001085082932
更新日: 2024年01月30日
野村 尚吾
ノムラ ショウゴ | Nomura Shogo
所属機関・部署：
職名：
特任講師
その他の所属（所属・部署名・職名） (1件)：
-
国立がん研究センター 研究支援センター
特任研究員
競争的資金等の研究課題 (1件)：
- 2013 - 2016 沖縄県におけるHTLV-1キャリア分布の解明および基盤データベースの構築
論文 (90件)：
-
Chikako Nakai, Sachiyo Mimaki, Koutatsu Matsushima, Eiji Shinozaki, Kentaro Yamazaki, Kei Muro, Kensei Yamaguchi, Tomohiro Nishina, Satoshi Yuki, Kohei Shitara, et al. Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant. International Journal of Clinical Oncology. 2023
-
Kohei Nakachi, Masafumi Ikeda, Masaru Konishi, Shogo Nomura, Hiroshi Katayama, Tomoko Kataoka, Akiko Todaka, Hiroaki Yanagimoto, Soichiro Morinaga, Shogo Kobayashi, et al. Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet (London, England). 2023. 401. 10372. 195-203
-
Yutaro Tamiya, Shingo Matsumoto, Yoshitaka Zenke, Kiyotaka Yoh, Takaya Ikeda, Yuji Shibata, Terufumi Kato, Kazumi Nishino, Atsushi Nakamura, Naoki Furuya, et al. Large-scale clinico-genomic profile of non-small cell lung cancer with KRAS G12C: Results from LC-SCRUM-Asia study. Lung cancer (Amsterdam, Netherlands). 2022. 176. 103-111
-
Chigusa Morizane, Nozomu Machida, Yoshitaka Honma, Takuji Okusaka, Narikazu Boku, Ken Kato, Shogo Nomura, Nobuyoshi Hiraoka, Shigeki Sekine, Hirokazu Taniguchi, et al. Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial. JAMA oncology. 2022. 8. 10. 1447-1455
-
Takashi Kojima, Ken Kato, Hiroki Hara, Shunji Takahashi, Kei Muro, Tomohiro Nishina, Masashi Wakabayashi, Shogo Nomura, Akihiro Sato, Atsushi Ohtsu, et al. Phase II study of BKM120 in patients with advanced esophageal squamous cell carcinoma (EPOC1303). Esophagus : official journal of the Japan Esophageal Society. 2022. 19. 4. 702-710
もっと見る
MISC (37件)：
-
Kentaro Yamazaki, Satoshi Yuki, Hiroya Taniguchi, Hideaki Bando, Yu Sunakawa, Manabu Shiozawa, Hisateru Yasui, Naoki Takahashi, Hironaga Satake, Nobuhisa Matsuhashi, et al. Impact of plasma VEGF-A, VEGF-D and PlGF on the efficacy of 2nd-line chemotherapy combined with biologics in mCRC. ANNALS OF ONCOLOGY. 2022. 33. S479-S479
-
Satoshi Yuki, Yu Sunakawa, Kentaro Yamazaki, Hiromichi Shirasu, Hiroya Taniguchi, Toshiki Masuishi, Manabu Shiozawa, Hideaki Bando, Tomohiro Nishina, Hisateru Yasui, et al. Analysis of plasma angiogenesis factors on the efficacy of first-line (1L) chemotherapy (chemo) combined with biologics in RAS wild-type metastatic colorectal cancer (mCRC): Results from GI-SCREEN CRC Ukit study. JOURNAL OF CLINICAL ONCOLOGY. 2022. 40. 16
-
Yu Sunakawa, Satoshi Yuki, Manabu Shiozawa, Toshiki Masuishi, Tomohiro Nishina, Hisateru Yasui, Takashi Ohta, Naoki Takahashi, Hironaga Satake, Akiyoshi Kanazawa, et al. Profiling plasma angiogenesis factors after use of biologics in metastatic colorectal cancer (mCRC): Update results from GI-SCREEN CRC Ukit study. JOURNAL OF CLINICAL ONCOLOGY. 2021. 39. 15
-
Masataka Yagisawa, Yoshiaki Nakamura, Takayuki Yoshino, Yoshito Komatsu, Shigenori Kadowaki, Kei Muro, Yu Sunakawa, Taroh Satoh, Tomohiro Nishina, Taito Esaki, et al. A basket trial of trastuzumab deruxtecan, a HER2-targeted antibody-drug conjugate, for HER2-amplified solid tumors identified by circulating tumor DNA analysis (HERALD trial). JOURNAL OF CLINICAL ONCOLOGY. 2020. 38. 15
-
Tomohiro Kadota, Daisuke Kotani, Yusuke Yoda, Miki Fukutani, Masashi Wakabayashi, Shogo Nomura, Nozomu Fuse, Akihiro Sato, Tomonori Yano, Kohei Shitara. A phase Ib study of near infrared photoimmunotherapy (NIR-PIT) using ASP-1929 in combination with nivolumab and for patients with advanced gastric or esophageal cancer (GE-PIT study, EPOC1901). JOURNAL OF CLINICAL ONCOLOGY. 2020. 38. 4
もっと見る
前のページに戻る
